Startups
Diurnal is an innovative UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
Since our inception in 2004, our company mission has been clear: to address crucial unmet patient and clinical need in the endocrine field and deliver best health outcomes to improve patients’ quality of life.
Diurnal has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
Since our inception in 2004, our company mission has been clear: to address crucial unmet patient and clinical need in the endocrine field and deliver best health outcomes to improve patients’ quality of life.
Diurnal has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
Overview
Location
United Kingdom, Wales, Cardiff
Employees
11-50
Founded date
2004
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 15, 2021 | Diurnal : Directorate Changes | Appointment of Chairman and two Non-Executive Directors with extensive industry experience to support commercial growth Anders Härfstrand, Deborah Jorn, and Jean-Michel Cosséry will join the Board with immediate effect Diurnal Group plc (AI... |
| Oct 14, 2021 | Diurnal : Distribution agreement signed with ExCEEd Orphan for Central and Eastern Europe | Agreement extends the Company's commercial footprint to over two-thirds of the European Economic Area population Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) dise... |
| Oct 11, 2021 | Diurnal : Phase 1 data for DITEST™ published in European Journal of Endocrinology | US IND submission for the Company's third novel product expected in Q4 2021 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the results from... |
| Sep 14, 2021 | Diurnal : Full Year Results for the year ended 30 June 2021 | Results for the year ended 30 June 2021 Significant progress made during the year with two major regulatory approvals Alkindi® growth of 18% in core markets despite continued impact of Covid-19 on hospital visits Post-period, launch of Efmo... |
| Sep 13, 2021 | Diurnal : Commercial launch of Efmody® in the UK | Commercial launch of Efmody® in the UK Follows recent European launch in Germany and Austria Provides a new treatment option for adult and adolescent patients suffering from CAH in the UK Diurnal Group plc (AIM: DNL), the specialty pharmace... |
| Sep 1, 2021 | Diurnal : launches Efmody® in Germany and Austria | Diurnal launches Efmody® in Germany and Austria Represents Diurnal's second marketed product in Europe Provides a new treatment option for adult and adolescent patients suffering from CAH Diurnal Group plc (AIM: DNL), the specialty pharmace... |
| Jul 28, 2021 | Diurnal : Business and trading update - July 2021 | Alkindi® growth of 18% in core markets despite continued impact of Covid-19 on hospital visits Efmody® European commercial preparations well-progressed with first market launch in Q3 2021 Efmody® US Phase 3 CAH study on track to commence in... |
| Jul 12, 2021 | Diurnal : receives Special Protocol Assessment Agreement for Chronocort® from the FDA | Pivotal Phase 3 trial expected to commence in the US in H2 2021 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces that the US Food and Drug A... |
| Jul 2, 2021 | Diurnal : receives Marketing Authorisation for Efmody® in Great Britain from the MHRA | Efmody® provides a new treatment option for c.5,000 patients suffering from CAH in GB GB launch of Efmody® expected in Q1 2022 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (... |
Show more
Reviews 0
FAQ about Diurnal
When was Diurnal founded?
Diurnal was founded in 2004.
What has the press written about Diurnal?
Parsers VC has collected 12 articles mentioning Diurnal, among them “Diurnal : Directorate Changes” (Nov 15, 2021) and “Diurnal : Distribution agreement signed with ExCEEd Orphan for Central and Eastern Europe” (Oct 14, 2021).
Is Diurnal still active?
Yes, Diurnal is active; its latest activity on Parsers VC dates from Nov 16, 2021.